We read with great interest the excellent article by Coriat et al. titled "Gastroenteropancreatic on Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement," published in The Oncologist [1] . The authors reviewed in detail the epidemiology and made recommendations for the management of this new entity. They concluded that Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs), Grade 3 (NET G-3), exist and differ from Poorly Differentiated (PD) GEP Neuroendocrine Carcinomas (NECs) in terms of prognosis.
NET G3 were included in those studies, provided that Ki-67 was unknown in tha main part of the tumors (on this basis the terms "G1" and "G2" should not be used). Furthermore, data on a limited number of patients with pancreatic NET G3 treated with everolimus were presented at the most recent European Neuroendocrine Tumor Society meeting (3).
Finally, we disagree with Coriat and colleagues' statement that bevacizumab was validated in pancreatic NECs, based on the current evidence. We believe that biological therapies, such as molecular targeted agents and somatostatin receptortargeted treatments, should be prospectively investigated in patients with advanced NET G3 in comparison with platinumbased chemotherapy, which is the current debatable standard treatment. 
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